Research Projects

Diabetes is known as the major worldwide problem currently. It is regarded as a metabolic syndrome. Several factors like insulin deficiency, insulin resistance, obesity etc. are major pathologies contributing factors. Diabetes causing a high rate of mortality and morbidity worldwide and currently affected more than 1/4 world’s adult population i.e. 415 million in 2015 and predicted to be rise 642 million by 2025. Diabetes Federation says that the cases of diabetes in India have more than doubled from 1995 (19.4 million) to 2013 (65.07 million), and are projected to increase approximately up to 57.2 million (approximately) by 2025. Treatment of diabetes includes lifestyle alterations, insulin therapy and oral hypoglycemic agents such as biguanides as insulin sensitizers (Metformin), alpha-glucosidase inhibitors reducing digestion of starch (Acarbose, Miglitol), meglitinides increases insulin secretion (Repaglinide, Nateglinide), dipeptidylpeptidase 4 (DPP-4) inhibitors increasing insulin secretion (Sitagliptin, Saxagliptin), and PPAR-gamma agonists (Thiazolidinediones: Trogliazone, Rosiglitazone, Pioglitazone). PPAR-gamma, is an established molecular target of thiazolidinediones, is particularly involved in the regulation of glucose metabolism, insulin sensitivity, fatty acid storage, and inflammation. So it represents as a fascinating pharmacological target enable to concurrently control different pathologies of metabolic disorder. PPARs activated by various ligands regulate the transcriptional activity. Natural ligands or molecules like thiazolidinone bind to PPARγ, leading to activation and complexation with retinoid X receptor (RXR) on DNA. Further, it forms heterodimers and binds to DNA via peroxisome proliferative response elements (PPREs). The use of so-called pan-PPAR agonists, which activate all three PPAR isoforms, is anticipated to increase efficacy compared to targeting a single or dual PPAR isoform and may bring an effective therapeutic approach. We have designed the several molecules based on the proposed pharmacophore using oxadiazole/triazole as a core structure and studied via in-silico drug design/docking which showed comparative results to pan PPAR agonist and better than our previously developed acrylic acid derivatives. With help of in-vitro and in-vivo evaluation these scaffolds will be extensively explored for possible treatment option for type 2 diabetes.